Literature DB >> 15382176

Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.

Douglas M Heuman1, Souheil G Abou-Assi, Adil Habib, Leslie M Williams, R Todd Stravitz, Arun J Sanyal, Robert A Fisher, Anastasios A Mihas.   

Abstract

Despite the adoption of "sickest first" liver transplantation, pretransplant death remains common, and many early deaths occur despite initially low Model for End-stage Liver Disease (MELD) scores. From 1997-2003, we studied 507 cirrhotic United States veterans referred for consideration of liver transplantation to identify additional predictors of early mortality. Most of the patients were male (98%) with cirrhosis caused by hepatitis C and/or alcohol (88%). Data for 296 patients referred prior to February 27, 2002 (training group), were analyzed; findings were validated in 211 patients referred subsequently (validation group). In the training group, 61 patients (21%) died within 180 days without transplantation; their median initial MELD score was 21. MELD score, persistent ascites, and low serum sodium (<135 meq/L) were independent predictors of early mortality. In patients with a MELD score of less than 21, only low serum sodium and persistent ascites were independent predictors of mortality; for MELD scores above 21, only MELD was independently predictive. Prognostic significance of persistent ascites and low serum sodium for low MELD score patients was confirmed in the validation group. Risk varied continuously with worsening hyponatremia. Modifying MELD, by including points for persistent ascites and low serum sodium, improved prediction of early pretransplant mortality in low MELD score patients. In conclusion, persistent ascites and low serum sodium identify patients with cirrhosis with high mortality risk despite low MELD scores. Ascites, hyponatremia, and other findings indicative of hemodynamic decompensation merit further prospective study as prognostic indicators in patients awaiting liver transplantation, and should be considered in setting minimal listing criteria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15382176     DOI: 10.1002/hep.20405

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  115 in total

1.  Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.

Authors:  Ma Somsouk; Rachel Kornfield; Eric Vittinghoff; John M Inadomi; Scott W Biggins
Journal:  Liver Transpl       Date:  2011-02       Impact factor: 5.799

2.  Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.

Authors:  Ming Zhang; Bo Li; Lu-Nan Yan; Fei Yin; Tian-Fu Wen; Yong Zeng; Ji-Chun Zhao; Yu-Kui Ma
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

3.  Access to liver transplantation in the MELD era: role of ethnicity and insurance.

Authors:  Nyingi Kemmer; Victoria Zacharias; Tiffany E Kaiser; Guy W Neff
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

4.  Factors contributing to the development of overt encephalopathy in liver cirrhosis patients.

Authors:  Motoh Iwasa; Ryosuke Sugimoto; Rumi Mifuji-Moroka; Nagisa Hara; Kyoko Yoshikawa; Hideaki Tanaka; Akiko Eguchi; Norihiko Yamamoto; Kazushi Sugimoto; Yoshinao Kobayashi; Hiroshi Hasegawa; Yoshiyuki Takei
Journal:  Metab Brain Dis       Date:  2016-06-29       Impact factor: 3.584

Review 5.  Living donor liver transplantation: eliminating the wait for death in end-stage liver disease?

Authors:  Robert A Fisher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-02-15       Impact factor: 46.802

Review 6.  Prioritization for liver transplantation.

Authors:  Evangelos Cholongitas; Giacomo Germani; Andrew K Burroughs
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

7.  Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis.

Authors:  Maximilian Jara; Tomasz Dziodzio; Maciej Malinowski; Katja Lüttgert; Radoslav Nikolov; Paul Viktor Ritschl; Robert Öllinger; Johann Pratschke; Martin Stockmann
Journal:  Dig Dis Sci       Date:  2018-11-07       Impact factor: 3.199

Review 8.  What's new in the treatment of ascites and spontaneous bacterial peritonitis.

Authors:  Andrés Cárdenas; Pere Ginès
Journal:  Curr Gastroenterol Rep       Date:  2008-02

9.  Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease.

Authors:  M Somsouk; J Guy; S W Biggins; E Vittinghoff; M A Kohn; J M Inadomi
Journal:  Aliment Pharmacol Ther       Date:  2009-07-13       Impact factor: 8.171

10.  Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.

Authors:  Allison J Kwong; Jennifer C Lai; Jennifer L Dodge; John P Roberts
Journal:  Liver Transpl       Date:  2015-11       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.